| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/AJH.2008.275 |
| P698 | PubMed publication ID | 18802434 |
| P2093 | author name string | Jean E Sealey | |
| John H Laragh | |||
| P2860 | cites work | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
| Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril | Q28215905 | ||
| Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients | Q28236175 | ||
| Renin and aldosterone suppression in the antihypertensive action of clonidine | Q28335367 | ||
| Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials | Q31132556 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| The captopril test for identifying renovascular disease in hypertensive patients | Q34181646 | ||
| Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research | Q34768060 | ||
| Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness | Q36813497 | ||
| Interpretation of plasma renin concentration in patients receiving aliskiren therapy | Q36993930 | ||
| Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors | Q37132667 | ||
| Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact | Q37253156 | ||
| Moderate sodium restriction. Do the benefits justify the hazards? | Q37819575 | ||
| Prediction of salt sensitivity | Q37940952 | ||
| Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt | Q44087075 | ||
| Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? | Q44269009 | ||
| Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren | Q44642058 | ||
| Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients | Q44710147 | ||
| Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption | Q45173412 | ||
| Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats | Q46587391 | ||
| Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial | Q46732967 | ||
| Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension | Q46842382 | ||
| Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension | Q46842411 | ||
| Plasma renin activity for predicting antihypertensive drug efficacy | Q46842414 | ||
| Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. | Q48342135 | ||
| Neurohumoral and Metabolic Effects of Short-Term Dietary NaCl Restriction in Men Relationship to Salt-Sensitivity Status | Q51611143 | ||
| Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. | Q55042824 | ||
| Detection of renovascular hypertension with angiotensin II blockade | Q67554556 | ||
| Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension | Q67800103 | ||
| Hypertension and chronic renal failure | Q68625396 | ||
| Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients | Q69557377 | ||
| Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise | Q70228849 | ||
| Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity | Q71487404 | ||
| Divergent blood pressure responses during short-term sodium restriction in hypertension | Q72127265 | ||
| Laragh's lessons in pathophysiology and clinical pearls for treating hypertension | Q73699370 | ||
| Laragh's lessons in pathophysiology and clinical pearls for treating hypertension | Q73834107 | ||
| Laragh's lessons in pathophysiology and clinical pearls for treating hypertension | Q73916950 | ||
| Laragh's lessons in pathophysiology and clinical pearls for treating hypertension | Q74039009 | ||
| Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension | Q74819950 | ||
| Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension | Q79970241 | ||
| Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension | Q80523350 | ||
| A brief response to Sealey and Laragh | Q80805591 | ||
| The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren | Q80972193 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 112-121 | |
| P577 | publication date | 2008-09-18 | |
| P1433 | published in | Journal of Clinical Hypertension | Q15762840 |
| P1476 | title | Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises | |
| P478 | volume | 22 |
| Q37598488 | Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology |
| Q37720499 | Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy |
| Q44356207 | Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively |
| Q37812374 | Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System |
| Q37854607 | Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results |
| Q37878706 | Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues |
| Q41788525 | Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is corre |
| Q95817434 | Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Sympathetic activation is the dominant contributor to |
| Q38088975 | Direct renin inhibition: extricating facts from façades |
| Q37574913 | Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination |
| Q37727965 | Is there a future for direct renin inhibitors? |
| Q90446723 | Juxtaglomerular Cell Tumor: Reviewing a Cryptic Cause of Surgically Correctable Hypertension |
| Q37777002 | New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren |
| Q37812140 | Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment |
| Q46047741 | Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial |
| Q84774641 | Pressor responses to antihypertensive drug types |
| Q46049607 | Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension |
| Q30491698 | Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data |
| Q37629835 | Recent changes in the landscape of combination RAS blockade |
| Q53212067 | Renin test-guided drug treatment of hypertension: the need for clinical trials. |
| Q84792932 | Renin-Guided Treatment of Hypertension: Time for Action |
| Q84465799 | Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors |
| Q34608252 | Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. |
| Q37654714 | Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage |
| Q48636756 | The Potential Role of Primary Care in Case Detection/Screening of Primary Aldosteronism. |
| Q37628444 | The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? |
| Q37936785 | The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure |
| Q37750291 | Unmet needs in managing hypertension: potential role of direct renin inhibition |
| Q43287463 | Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugs |
| Q34114402 | Vaccines in the management of hypertension |
Search more.